FDA approves Teva's WELTRUZA, the first once-monthly subcutaneous olanzapine shot for schizophrenia - no loading doses, no observation required.
FDA approves Teva's WELTRUZA, the first once-monthly subcutaneous olanzapine shot for schizophrenia - no loading doses, no observation required.